{"nctId":"NCT03760146","briefTitle":"Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naÃ¯ve Adults","startDateStruct":{"date":"2018-12-12","type":"ACTUAL"},"conditions":["Pneumococcal Disease"],"count":3902,"armGroups":[{"label":"60 years and above 20vPnC/Saline","type":"EXPERIMENTAL","interventionNames":["Biological: 20vPnC","Other: Saline"]},{"label":"60 years and above 13vPnC/PPSV23","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 13vPnC","Biological: PPSV23"]},{"label":"50 through 59 years of age 20vPnC","type":"EXPERIMENTAL","interventionNames":["Biological: 20vPnC"]},{"label":"18 through 49 years of age 20vPnC","type":"EXPERIMENTAL","interventionNames":["Biological: 20vPnC"]},{"label":"50 through 59 years of age 13vPnC","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 13vPnC"]},{"label":"18 through 49 years of age 13vPnC","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 13vPnC"]}],"interventions":[{"name":"20vPnC","otherNames":[]},{"name":"13vPnC","otherNames":[]},{"name":"PPSV23","otherNames":["Pneumovax 23"]},{"name":"Saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female adults \\>/= 18 years of age (from the 18th birthday) at enrollment and older.\n2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.\n3. Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.\n\nExclusion Criteria:\n\n1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.\n2. History of microbiologically proven invasive disease caused by S pneumoniae.\n3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.\n4. Pregnant female subjects or breastfeeding female subjects.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts","description":"Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \\[\\>\\] 2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm) and severe (\\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"6.2","spread":null},{"groupId":"OG002","value":"8.2","spread":null},{"groupId":"OG003","value":"5.4","spread":null},{"groupId":"OG004","value":"9.0","spread":null},{"groupId":"OG005","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"5.1","spread":null},{"groupId":"OG003","value":"2.7","spread":null},{"groupId":"OG004","value":"3.0","spread":null},{"groupId":"OG005","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"2.7","spread":null},{"groupId":"OG003","value":"2.7","spread":null},{"groupId":"OG004","value":"5.4","spread":null},{"groupId":"OG005","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0.3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.6","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"8.8","spread":null},{"groupId":"OG003","value":"10.8","spread":null},{"groupId":"OG004","value":"11.6","spread":null},{"groupId":"OG005","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"5.7","spread":null},{"groupId":"OG003","value":"7.2","spread":null},{"groupId":"OG004","value":"7.2","spread":null},{"groupId":"OG005","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"3.0","spread":null},{"groupId":"OG003","value":"3.6","spread":null},{"groupId":"OG004","value":"4.5","spread":null},{"groupId":"OG005","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"54.1","spread":null},{"groupId":"OG002","value":"72.5","spread":null},{"groupId":"OG003","value":"69.4","spread":null},{"groupId":"OG004","value":"81.2","spread":null},{"groupId":"OG005","value":"82.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"53.5","spread":null},{"groupId":"OG003","value":"52.3","spread":null},{"groupId":"OG004","value":"42.7","spread":null},{"groupId":"OG005","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"9.2","spread":null},{"groupId":"OG002","value":"17.8","spread":null},{"groupId":"OG003","value":"16.2","spread":null},{"groupId":"OG004","value":"38.2","spread":null},{"groupId":"OG005","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.3","spread":null},{"groupId":"OG002","value":"1.2","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"0.3","spread":null},{"groupId":"OG005","value":"0.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination in All Cohorts","description":"Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an electronic diary. Fever was defined as greater than or equal to (\\>=) 38.0 degree Celsius (C) and categorized to \\>=38.0 to 38.4 degree C, \\>38.4 to 38.9 degree C, \\>38.9 to 40.0 degree C and \\>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.8","spread":null},{"groupId":"OG002","value":"1.5","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"1.2","spread":null},{"groupId":"OG005","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"0.6","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0.3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.3","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.3","spread":null},{"groupId":"OG005","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0.3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"30.7","spread":null},{"groupId":"OG002","value":"39.3","spread":null},{"groupId":"OG003","value":"36.0","spread":null},{"groupId":"OG004","value":"42.7","spread":null},{"groupId":"OG005","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"17.5","spread":null},{"groupId":"OG002","value":"21.1","spread":null},{"groupId":"OG003","value":"18.0","spread":null},{"groupId":"OG004","value":"18.8","spread":null},{"groupId":"OG005","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"11.9","spread":null},{"groupId":"OG002","value":"17.2","spread":null},{"groupId":"OG003","value":"15.3","spread":null},{"groupId":"OG004","value":"22.1","spread":null},{"groupId":"OG005","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"0.9","spread":null},{"groupId":"OG003","value":"2.7","spread":null},{"groupId":"OG004","value":"1.8","spread":null},{"groupId":"OG005","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"23.3","spread":null},{"groupId":"OG002","value":"32.3","spread":null},{"groupId":"OG003","value":"36.0","spread":null},{"groupId":"OG004","value":"38.8","spread":null},{"groupId":"OG005","value":"33.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"17.0","spread":null},{"groupId":"OG002","value":"20.5","spread":null},{"groupId":"OG003","value":"21.6","spread":null},{"groupId":"OG004","value":"21.5","spread":null},{"groupId":"OG005","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"10.9","spread":null},{"groupId":"OG003","value":"13.5","spread":null},{"groupId":"OG004","value":"14.6","spread":null},{"groupId":"OG005","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.3","spread":null},{"groupId":"OG002","value":"0.9","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"2.7","spread":null},{"groupId":"OG005","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"37.3","spread":null},{"groupId":"OG002","value":"49.8","spread":null},{"groupId":"OG003","value":"49.5","spread":null},{"groupId":"OG004","value":"66.6","spread":null},{"groupId":"OG005","value":"74.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"26.8","spread":null},{"groupId":"OG002","value":"33.8","spread":null},{"groupId":"OG003","value":"31.5","spread":null},{"groupId":"OG004","value":"36.4","spread":null},{"groupId":"OG005","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"15.4","spread":null},{"groupId":"OG003","value":"17.1","spread":null},{"groupId":"OG004","value":"29.0","spread":null},{"groupId":"OG005","value":"31.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"1.2","spread":null},{"groupId":"OG005","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"13.7","spread":null},{"groupId":"OG002","value":"15.4","spread":null},{"groupId":"OG003","value":"20.7","spread":null},{"groupId":"OG004","value":"13.4","spread":null},{"groupId":"OG005","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"10.6","spread":null},{"groupId":"OG003","value":"12.6","spread":null},{"groupId":"OG004","value":"6.3","spread":null},{"groupId":"OG005","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"4.8","spread":null},{"groupId":"OG003","value":"7.2","spread":null},{"groupId":"OG004","value":"7.2","spread":null},{"groupId":"OG005","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All Cohorts","description":"An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"11.1","spread":null},{"groupId":"OG002","value":"10.2","spread":null},{"groupId":"OG003","value":"8.1","spread":null},{"groupId":"OG004","value":"15.2","spread":null},{"groupId":"OG005","value":"11.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All Cohorts","description":"An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"0.3","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"0.6","spread":null},{"groupId":"OG005","value":"0.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All Cohorts","description":"An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null},{"groupId":"OG002","value":"1.5","spread":null},{"groupId":"OG003","value":"0.9","spread":null},{"groupId":"OG004","value":"1.5","spread":null},{"groupId":"OG005","value":"1.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population","description":"OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123.4","spread":null},{"groupId":"OG001","value":"153.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null},{"groupId":"OG001","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"508.7","spread":null},{"groupId":"OG001","value":"626.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"109.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"889.0","spread":null},{"groupId":"OG001","value":"1165.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1115.2","spread":null},{"groupId":"OG001","value":"1341.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"968.8","spread":null},{"groupId":"OG001","value":"1129.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1455.5","spread":null},{"groupId":"OG001","value":"1567.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"746.7","spread":null},{"groupId":"OG001","value":"746.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1252.6","spread":null},{"groupId":"OG001","value":"1482.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"517.9","spread":null},{"groupId":"OG001","value":"645.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"265.8","spread":null},{"groupId":"OG001","value":"333.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"276.5","spread":null},{"groupId":"OG001","value":"335.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Pneumococcal OPA GMTs for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population (E7-AIP)","description":"OPA GMTs were determined for serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"465.6","spread":null},{"groupId":"OG001","value":"848.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2007.6","spread":null},{"groupId":"OG001","value":"1079.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4426.8","spread":null},{"groupId":"OG001","value":"2534.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2538.7","spread":null},{"groupId":"OG001","value":"1716.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2398.2","spread":null},{"groupId":"OG001","value":"768.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3666.2","spread":null},{"groupId":"OG001","value":"1846.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5125.9","spread":null},{"groupId":"OG001","value":"3720.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Pneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 2, 50 Through 59 Years of Age and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population","description":"OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135.9","spread":null},{"groupId":"OG001","value":"131.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":null},{"groupId":"OG001","value":"40.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"633.3","spread":null},{"groupId":"OG001","value":"577.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1203.9","spread":null},{"groupId":"OG001","value":"997.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1502.7","spread":null},{"groupId":"OG001","value":"1199.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1047.0","spread":null},{"groupId":"OG001","value":"1173.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1725.7","spread":null},{"groupId":"OG001","value":"1687.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"926.2","spread":null},{"groupId":"OG001","value":"742.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1805.0","spread":null},{"groupId":"OG001","value":"1355.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"618.4","spread":null},{"groupId":"OG001","value":"600.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"286.7","spread":null},{"groupId":"OG001","value":"290.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"549.1","spread":null},{"groupId":"OG001","value":"327.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"486.9","spread":null},{"groupId":"OG001","value":"502.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2520.4","spread":null},{"groupId":"OG001","value":"2437.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6416.9","spread":null},{"groupId":"OG001","value":"5248.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3445.1","spread":null},{"groupId":"OG001","value":"3105.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3355.9","spread":null},{"groupId":"OG001","value":"2873.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3808.1","spread":null},{"groupId":"OG001","value":"4228.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5571.3","spread":null},{"groupId":"OG001","value":"5445.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Pneumococcal OPA GMTs for the 20 Vaccines Serotypes at 1 Month After 20vPnC Vaccination in Cohort 3, 18 Through 49 Years and Cohort 1, Only 60 Through 64 Years of Age: Evaluable-20 Immunogenicity Population","description":"OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA geometric mean and 2-sided 95% CIs were calculated.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.6","spread":null},{"groupId":"OG001","value":"132.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1966.7","spread":null},{"groupId":"OG001","value":"594.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.9","spread":null},{"groupId":"OG001","value":"96.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3930.5","spread":null},{"groupId":"OG001","value":"1022.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4260.0","spread":null},{"groupId":"OG001","value":"1250.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1872.8","spread":null},{"groupId":"OG001","value":"1187.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6041.4","spread":null},{"groupId":"OG001","value":"1726.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1848.4","spread":null},{"groupId":"OG001","value":"772.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4460.5","spread":null},{"groupId":"OG001","value":"1395.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1415.0","spread":null},{"groupId":"OG001","value":"611.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"654.8","spread":null},{"groupId":"OG001","value":"301.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1559.2","spread":null},{"groupId":"OG001","value":"324.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"867.0","spread":null},{"groupId":"OG001","value":"508.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4157.3","spread":null},{"groupId":"OG001","value":"2569.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7169.3","spread":null},{"groupId":"OG001","value":"5419.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5875.4","spread":null},{"groupId":"OG001","value":"3074.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4601.0","spread":null},{"groupId":"OG001","value":"3019.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7568.2","spread":null},{"groupId":"OG001","value":"4482.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7976.9","spread":null},{"groupId":"OG001","value":"5693.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Pneumococcal OPA Geometric Mean Fold Rises (GMFRs) for the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population","description":"OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"42.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"26.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"37.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":null},{"groupId":"OG001","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Pneumococcal OPA GMFRs for the Additional 7 Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population","description":"OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null},{"groupId":"OG001","value":"37.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Pneumococcal OPA GMFRs for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population","description":"OPA GMFR is the ratio of OPA GMT, 1 month after vaccination to before vaccination OPA GMT. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"131.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":null},{"groupId":"OG001","value":"146.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"35.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null},{"groupId":"OG001","value":"111.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":null},{"groupId":"OG001","value":"39.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null},{"groupId":"OG001","value":"118.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"34.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.3","spread":null},{"groupId":"OG001","value":"171.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"65.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":null},{"groupId":"OG001","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers to the 13 Matched Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population","description":"Percentage of participants with a \\>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"61.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"60.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null},{"groupId":"OG001","value":"84.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"77.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null},{"groupId":"OG001","value":"72.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null},{"groupId":"OG001","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null},{"groupId":"OG001","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null},{"groupId":"OG001","value":"77.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"66.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"74.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 7 Additional Serotypes From Before Vaccination 1 to 1 Month After Vaccination 1(20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2(PPSV23) in Cohort 1:E7-AIP","description":"Percentage of participants with a \\>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"86.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"51.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"80.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"63.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"76.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null},{"groupId":"OG001","value":"55.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers for the 20 Vaccines Serotypes From Before Vaccination to 1 Month After Vaccination in Cohort 2 and 3: Evaluable-20 Immunogenicity Population","description":"Percentage of participants with a \\>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","spread":null},{"groupId":"OG001","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null},{"groupId":"OG001","value":"56.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"64.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"89.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null},{"groupId":"OG001","value":"84.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null},{"groupId":"OG001","value":"62.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"82.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.4","spread":null},{"groupId":"OG001","value":"83.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":null},{"groupId":"OG001","value":"78.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"93.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"73.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null},{"groupId":"OG001","value":"83.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"60.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pneumococcal OPA Titers >= Lower Limit of Quantitation (LLOQ) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity Population","description":"The percentage of participants with OPA titers \\>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"76.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null},{"groupId":"OG001","value":"91.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"81.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"83.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population","description":"The percentage of participants with OPA titers \\>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"95.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"94.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"92.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pneumococcal OPA Titers >=LLOQ for the 20 Vaccines Serotypes at 1 Month After Vaccination (20vPnC) in Cohort 2 and 3: Evaluable-20 Immunogenicity Population","description":"The percentage of participants with OPA titers \\>=LLOQ along with corresponding 2-sided 95% CIs were calculated 1 month after vaccination for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure were planned to be analyzed for the 20vPnC groups of Cohorts 2 and 3 only.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"96.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":1507},"commonTop":["Injection site pain (PAIN)","Myalgia (MUSCLE PAIN)","Fatigue (FATIGUE)","Headache (HEADACHE)","Arthralgia (JOINT PAIN)"]}}}